德国勃林格殷格翰的思力华适用于什么病症？

(Repimat) is a long-term effective anticholinergic agent. Patients with chronic obstructive pulmonary disease have strong relaxation of the lost nerves. Slivar can effectively prevent the relaxation of the lost nerves in patients with chronic obstructive pulmonary disease, allowing the nerves to contract smoothly. As a new drug delivery form launched in my country, Spiriva of Germany's Boehringer Ingelheim is widely used in clinical applications because it can be easily inhaled, the drug is efficiently deposited in the lungs, and it is easy to carry.

In order to explore the application effect of Siliva in the treatment of stable chronic obstructive pulmonary disease, a domestic study selected 298 patients with confirmed chronic obstructive pulmonary disease and randomly divided them into two groups of 149 patients each. The control group was given aminophylline, and the observation group was given Sliva. The lung function indicators and adverse reactions of the two groups were compared.

The final results showed that after treatment, the FEV1 of the observation group increased to (2.01±0.15)L, the FEV1/FVC increased to (65.02 ±3.76)%, and the predicted FEV1 value increased to (59.04 ±4.21)%, which were all better than those of the control group, and the difference was statistically significant (P<0.05). After treatment, the pulmonary function increase index of the observation group was significantly better than that of the control group (P<0.05). The incidence of adverse reactions in the observation group was 3.3%, while the incidence rate of adverse reactions in the control group was 10.7%. The difference was statistically significant (P<0.05). It can be seen that Silihua has significant clinical efficacy in treating stable chronic obstructive pulmonary disease and is worthy of application.

The main research areas of Boehringer Ingelheim in Germany include: immune and respiratory diseases, cardiovascular and metabolic diseases, central nervous diseases, and tumors. The chronic obstructive pulmonary disease (COPD) treatment drugs it developed have been approved for marketing in China, providing great convenience for many patients to purchase drugs. Patients in need can either purchase drugs domestically or contact medical companions to purchase drugs overseas.

Recommended hot articles: /newsDetail/92311.html